FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111497195> ?p ?o ?g. }

• W2111497195 endingPage "719" @default.
• W2111497195 startingPage "713" @default.
• W2111497195 abstract "ObjectiveArteriovenous fistulas (AVFs) are the preferred choice for hemodialysis vascular access (AV access); however, there is debate over the utility of AVFs in older patients, particularly concerning access maturation and functionality. We reviewed our AV access experience in patients ≥65 years of age.MethodsWe analyzed consecutive AV access patients ≥65 years old with access operations between March 2003 and December 2009. All patients had ultrasound vessel mapping. In addition to overall outcomes review, the data for patients ≥65 years old were stratified into three 10-year increments by age for further analysis. We compared functional patency data for our older patients with those of our non-elderly patients aged 21 to 64 years treated during the same time period.ResultsFour hundred sixty-one consecutive AV access patients new to our practice were included in this study. Ages were 65 to 94 years (mean, 73 years). Two hundred thirty-six (51.2%) were female, 276 (59.9%) patients were diabetic, and 103 (22.3%) were obese. One hundred seven (23.2%) patients had previous access operations. Radiocephalic AVFs were constructed in 29 (6.3%) patients, 99 (21.5%) patients had brachial artery inflow AVFs, 330 (71.6%) had proximal radial artery AVFs, and three were based on the femoral artery. Transposition AVFs were used in 124 (26.9%) patients. No grafts were used for AV access in any patient during the study period. Time to AVF use was 0.5 to 6 months (mean, 1.5 months). Primary, primary assisted, and cumulative patency for patients aged 65 to 94 years were 59.9%, 93.7%, and 96.9% at 12 months and 45.3%, 90.1%, and 94.6% at 24 months, respectively. Follow-up was 1.5 to 77 months (mean, 17.0 months). Subgroup age stratification (65-74 [n = 268], 75-84 [n = 167], 85-94 [n = 26] years) found no statistical difference in functional access outcomes. Primary, primary assisted, and cumulative patency rates were not statistically different in the elderly and non-elderly populations (P = .29, .27, and .37, respectively). One hundred fifty-six patients died during the study period, 1.3 to 61 months (mean, 20 months) after access creation. No deaths were related to access operations.ConclusionsAVFs are feasible and offer functional and timely AV access in older patients. There was no difference in functional access outcomes for older patients with subgroup age stratification. AVF patency rates were not statistically different in the elderly and non-elderly populations. Cumulative AVF patency for patients ≥65 years of age was 96.9% at 12 months and 94.6% at 24 months. Arteriovenous fistulas (AVFs) are the preferred choice for hemodialysis vascular access (AV access); however, there is debate over the utility of AVFs in older patients, particularly concerning access maturation and functionality. We reviewed our AV access experience in patients ≥65 years of age. We analyzed consecutive AV access patients ≥65 years old with access operations between March 2003 and December 2009. All patients had ultrasound vessel mapping. In addition to overall outcomes review, the data for patients ≥65 years old were stratified into three 10-year increments by age for further analysis. We compared functional patency data for our older patients with those of our non-elderly patients aged 21 to 64 years treated during the same time period. Four hundred sixty-one consecutive AV access patients new to our practice were included in this study. Ages were 65 to 94 years (mean, 73 years). Two hundred thirty-six (51.2%) were female, 276 (59.9%) patients were diabetic, and 103 (22.3%) were obese. One hundred seven (23.2%) patients had previous access operations. Radiocephalic AVFs were constructed in 29 (6.3%) patients, 99 (21.5%) patients had brachial artery inflow AVFs, 330 (71.6%) had proximal radial artery AVFs, and three were based on the femoral artery. Transposition AVFs were used in 124 (26.9%) patients. No grafts were used for AV access in any patient during the study period. Time to AVF use was 0.5 to 6 months (mean, 1.5 months). Primary, primary assisted, and cumulative patency for patients aged 65 to 94 years were 59.9%, 93.7%, and 96.9% at 12 months and 45.3%, 90.1%, and 94.6% at 24 months, respectively. Follow-up was 1.5 to 77 months (mean, 17.0 months). Subgroup age stratification (65-74 [n = 268], 75-84 [n = 167], 85-94 [n = 26] years) found no statistical difference in functional access outcomes. Primary, primary assisted, and cumulative patency rates were not statistically different in the elderly and non-elderly populations (P = .29, .27, and .37, respectively). One hundred fifty-six patients died during the study period, 1.3 to 61 months (mean, 20 months) after access creation. No deaths were related to access operations. AVFs are feasible and offer functional and timely AV access in older patients. There was no difference in functional access outcomes for older patients with subgroup age stratification. AVF patency rates were not statistically different in the elderly and non-elderly populations. Cumulative AVF patency for patients ≥65 years of age was 96.9% at 12 months and 94.6% at 24 months." @default.
• W2111497195 created "2016-06-24" @default.
• W2111497195 creator A5009836926 @default.
• W2111497195 creator A5027163834 @default.
• W2111497195 creator A5058587628 @default.
• W2111497195 creator A5083241240 @default.
• W2111497195 date "2011-03-01" @default.
• W2111497195 modified "2023-09-27" @default.
• W2111497195 title "Creating functional autogenous vascular access in older patients" @default.
• W2111497195 cites W11051636 @default.
• W2111497195 cites W1893896204 @default.
• W2111497195 cites W1949597025 @default.
• W2111497195 cites W1973031258 @default.
• W2111497195 cites W1977717186 @default.
• W2111497195 cites W1978778351 @default.
• W2111497195 cites W1982246196 @default.
• W2111497195 cites W1986862277 @default.
• W2111497195 cites W1994485674 @default.
• W2111497195 cites W1997733535 @default.
• W2111497195 cites W2009417247 @default.
• W2111497195 cites W2026385971 @default.
• W2111497195 cites W2031231480 @default.
• W2111497195 cites W2037399960 @default.
• W2111497195 cites W2049514151 @default.
• W2111497195 cites W2050834803 @default.
• W2111497195 cites W2054416715 @default.
• W2111497195 cites W2061671484 @default.
• W2111497195 cites W2065526676 @default.
• W2111497195 cites W2069665072 @default.
• W2111497195 cites W2079677504 @default.
• W2111497195 cites W2080496031 @default.
• W2111497195 cites W2082667722 @default.
• W2111497195 cites W2084001563 @default.
• W2111497195 cites W2096903098 @default.
• W2111497195 cites W2097738498 @default.
• W2111497195 cites W2101141985 @default.
• W2111497195 cites W2115835856 @default.
• W2111497195 cites W2140758664 @default.
• W2111497195 cites W2142226991 @default.
• W2111497195 cites W2146404098 @default.
• W2111497195 cites W2148123975 @default.
• W2111497195 cites W2155647147 @default.
• W2111497195 cites W2157260213 @default.
• W2111497195 cites W2157451020 @default.
• W2111497195 cites W2168483664 @default.
• W2111497195 cites W2168713667 @default.
• W2111497195 cites W2169328204 @default.
• W2111497195 cites W2220374493 @default.
• W2111497195 doi "https://doi.org/10.1016/j.jvs.2010.09.057" @default.
• W2111497195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21129897" @default.
• W2111497195 hasPublicationYear "2011" @default.
• W2111497195 type Work @default.
• W2111497195 sameAs 2111497195 @default.
• W2111497195 citedByCount "45" @default.
• W2111497195 countsByYear W21114971952012 @default.
• W2111497195 countsByYear W21114971952013 @default.
• W2111497195 countsByYear W21114971952014 @default.
• W2111497195 countsByYear W21114971952015 @default.
• W2111497195 countsByYear W21114971952016 @default.
• W2111497195 countsByYear W21114971952017 @default.
• W2111497195 countsByYear W21114971952018 @default.
• W2111497195 countsByYear W21114971952019 @default.
• W2111497195 countsByYear W21114971952020 @default.
• W2111497195 countsByYear W21114971952021 @default.
• W2111497195 countsByYear W21114971952022 @default.
• W2111497195 countsByYear W21114971952023 @default.
• W2111497195 crossrefType "journal-article" @default.
• W2111497195 hasAuthorship W2111497195A5009836926 @default.
• W2111497195 hasAuthorship W2111497195A5027163834 @default.
• W2111497195 hasAuthorship W2111497195A5058587628 @default.
• W2111497195 hasAuthorship W2111497195A5083241240 @default.
• W2111497195 hasBestOaLocation W21114971951 @default.
• W2111497195 hasConcept C126322002 @default.
• W2111497195 hasConcept C141071460 @default.
• W2111497195 hasConcept C2776016174 @default.
• W2111497195 hasConcept C2777604165 @default.
• W2111497195 hasConcept C2778063415 @default.
• W2111497195 hasConcept C2779063477 @default.
• W2111497195 hasConcept C2779723990 @default.
• W2111497195 hasConcept C3019775111 @default.
• W2111497195 hasConcept C71924100 @default.
• W2111497195 hasConcept C84393581 @default.
• W2111497195 hasConceptScore W2111497195C126322002 @default.
• W2111497195 hasConceptScore W2111497195C141071460 @default.
• W2111497195 hasConceptScore W2111497195C2776016174 @default.
• W2111497195 hasConceptScore W2111497195C2777604165 @default.
• W2111497195 hasConceptScore W2111497195C2778063415 @default.
• W2111497195 hasConceptScore W2111497195C2779063477 @default.
• W2111497195 hasConceptScore W2111497195C2779723990 @default.
• W2111497195 hasConceptScore W2111497195C3019775111 @default.
• W2111497195 hasConceptScore W2111497195C71924100 @default.
• W2111497195 hasConceptScore W2111497195C84393581 @default.
• W2111497195 hasIssue "3" @default.
• W2111497195 hasLocation W21114971951 @default.
• W2111497195 hasLocation W21114971952 @default.
• W2111497195 hasOpenAccess W2111497195 @default.
• W2111497195 hasPrimaryLocation W21114971951 @default.
• W2111497195 hasRelatedWork W113810927 @default.

• next